Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;12(Suppl 1):S37-S40.
doi: 10.5005/jp-journals-10018-1376.

Nonalcoholic Fatty Liver Disease in Diabetics: The Role of Hepatologist

Reshu Khandelwal  1 , Anuradha Supun Dassanayake  2 , Shivaram Prasad Singh  3
Affiliations
Review

Nonalcoholic Fatty Liver Disease in Diabetics: The Role of Hepatologist

Reshu Khandelwal et al. Euroasian J Hepatogastroenterol. 2022 Jul.

Abstract

Diabetes mellitus is one of the most prevalent metabolic diseases worldwide, causing an enormous burden on the economies of both developed and developing nations. Nonalcoholic fatty liver disease (NAFLD) is very closely associated with diabetes, and the two diseases are known to cause an increase in morbidity and mortality. Timely referral of a diabetic with NAFLD to a hepatologist can definitely delay disease progression and the related complications. Despite the magnitude, there are no guidelines that recommend a screening algorithm that must be followed for evaluating NAFLD in at-risk diabetics at the primary care level and their further referral to hepatologists. Nonalcoholic fatty liver disease management needs heightened awareness among primary care physicians/endocrinologists and hepatologists, and a collaborative care approach is paramount in these patients. Certain antidiabetic drugs are found to be beneficial in the treatment of NAFLD patients with diabetes, however, none of them are FDA approved.

How to cite this article: Khandelwal R, Dassanayake AS, Singh SP. Nonalcoholic Fatty Liver Disease in Diabetics: The Role of Hepatologist. Euroasian J Hepato-Gastroenterol 2022;12(Suppl 1):S37-S40.

Keywords: Antidiabetic drugs; Diabetes; Fibrosis; Hepatologist; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis.

PubMed Disclaimer

Conflict of interest statement

Source of support: Nil Conflict of interest: None

Figures

Fig. 1
Fig. 1
Type 2 diabetes and NAFLD: an intricate affair
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Pepper W. Saccharine diabetes. Med Rec. 1884;25:9–12.
    1. Connor CL. Fatty infiltration of the liver and the development of cirrhosis in diabetes and chronic alcoholism. Am J Pathol. 1938;14(3):347–364. 19970395 - PMC - PubMed
    1. Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20(2):12. doi: 10.1007/s11906-018-0812-z. - DOI - PMC - PubMed
    1. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30(5):1212–1218. doi: 10.2337/dc06-2247. - DOI - PubMed
    1. Williamson RM, Price JF, Glancy S, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011;34(5):1139–1144. doi: 10.2337/dc10-2229. - DOI - PMC - PubMed